| Date | Title | | | 11/06/06 | Raptor Pharmaceuticals Corp. Announces an Exclusive Worldwide License Agreement for Mesd Reagents for Treatment of Cancer and Osteoporosis| Novato, California, November 6, 2006 – Raptor Pharmaceuticals Corp. (the "Company") (OTC Bulletin
Board: RPTP.OB), today announced that effective November 2, 2006 its wholly-owned subsidiary, Raptor
Pharmaceutical Inc., signed an exclusive worldwide license agreement for the use of Mesd reagents for
therapeutic treatment of cancer and osteoporosis with Washington University, St. Louis. Mesd is a
chaperone protein necessary for the proper folding of the signal transduction receptors LRP5 and ... |
|  | | 09/11/06 | Raptor Raptor Pharmaceutical Inc. Announces the Establishment of its Medical and Scientific Advisory Board|
Novato, California, September 11, 2006 – Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP.OB), today announced that its wholly-owned subsidiary, Raptor Pharmaceutical Inc. (“Raptor”), has formally established its Medical and Scientific Advisory Board. Board members will provide Raptor's business team with scientific, medical, strategic and business input into its research and development programs.
“We are pleased to have assembled a strong and diverse team of experienced advisors.... |
| | | 08/01/06 | Raptor Pharmaceuticals Corp. Announces Research Collaboration with Stanford University on the Use of NeuroTrans™ to Deliver Therapeutics Across the Blood-Brain Barrier| Novato, California, August 1, 2006 – Raptor Pharmaceuticals Corp. (the "Company") (OTC Bulletin Board: RPTP.OB), today announced that its wholly-owned subsidiary, Raptor Pharmaceutical Inc., has signed a research collaboration agreement with Dr. William Mobley, Professor of Neurology and Neurological Sciences at the Stanford School of Medicine and Director, Neuroscience Institute at Stanford commencing August 1, 2006.
Dr. Mobley's lab will study the utility of the Company's proprietary Recep... |
| | | 07/26/06 | Raptor Pharmaceuticals Corp. Announces Effectiveness of SEC Registration Statement| Novato, California, July 26, 2006 – Raptor Pharmaceuticals Corp. (the "Company") (OTC Bulletin Board: RPTP.OB), today announced that the U. S. Securities and Exchange Commission declared effective on July 10, 2006 the Company's registration statement on Form SB-2, relating to the resale of up to 18,266,666 shares of the Company's common stock, par value $0.001 per share, by certain selling stockholders. The Company was required to register these shares due to commitments it made in connection wi... |
| | | 05/26/06 | Raptor Pharmaceutical Inc. Closes a $5.0 Million Financing Concurrent with a Reverse Merger to Continue Development of Therapeutic Targeting Technology | Novato, California, May 26, 2006 - Raptor Pharmaceutical Inc. ("Raptor") announced today the completion of a reverse merger of Highland Clan Creations Corp. (OTCBB: HCLN) in a stock-for-stock exchange. Highland sold all of its prior operations as a nutritional drink distributor in April 2006. Effective June 9, 2006, Highland will reincorporate in Delaware from Nevada and will change its name to Raptor Pharmaceuticals Corp. Highland, which now owns 100% of the operating company, Raptor Pharmac... |
| |
|
